A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some significant safety challenges, such as cytokine release...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Erhao, Xu, Hanmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210295/
https://www.ncbi.nlm.nih.gov/pubmed/28049484
http://dx.doi.org/10.1186/s13045-016-0379-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210295/
https://www.ncbi.nlm.nih.gov/pubmed/28049484
http://dx.doi.org/10.1186/s13045-016-0379-6

Ejemplares similares